Calliditas Therapeutics AB’s phase 3 study looking at a cure for a kidney disease called IgA nephropathy (IgAN) has met its primary endpoint and the full data has been published in The Lancet.
Lupin Limited today announced the successful completion of the inspection carried out by the UK Medicines and Healthcare products Regulatory Agency at its Pithampur facilities in India.
PALO ALTO, Calif., May 31, 2022 (GLOBE NEWSWIRE) 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of